Перспективы использования Цетуксимаба при злокачественных опухолях толстой кишки и опухолях головы и шеи

1. Baselga J et al. Eur J Cancer 2001; 37: S16–22.
2. Saltz L, Rubin et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (abstr 7).
3. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958–70.
4. Damjanov N, Meropol NJ. Oncology 2004; 479–503.
5. Prewett M et al. Clin Cancer Res 2002; 8: 994–1003.
6. Merck. Data on file, GERBPK001. Merck KGaA.
7. Tournigand C, Andre T et al. FOLFIRI followed by FOLFOX6 or the reverse seguence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229–37.
8. Saltz L, Meropol NJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–08.
9. Lenz H-J, Mayer RJ et al. consistent reponse to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (16s): Abstract 3536.
10. Cunningham D, Humblet Y et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.
11. Scartozzi M et al. J Clin Oncol 2004; 22: 4772–8.
12. Wilke H, Glynne-Jones R et al. MABEL-a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. ASCO 2006; Abstr. 3549.
13. Souglakos J, Kalykaki A et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2006; 1: 1–6.
14. Saltz L et al. ASCO GI Symposium: 2005; abstr. 169b.
15. Siena S, Glynne-Jones R et al. MABEL: A large multinational study of cetuximab plus irinotecan in mCRC after irinotecan failure update on infusion-related reactions ASCO 2007; abstr. 353.
16. Van Cutsem E, Humblet Y et al. Cetuximab dose-escalation study in patients with nCRC with no or slight skin reactions on cetuximab standard dose treatment (EVEREST); preliminary PK and efficacy data of a randomized stidy. ASCO 2007; abstr. 237.
17. Tabernero J et al. Weekly vs Every-second – week IRBITUX schedule. ASCO 2007; abstr. LB-352.
18. Rosenberg M et al. ASCO 2002; Symposium, abstr. 536.
19. Folprecht G et al. ASCO 2005; Symposium, abstr. 283.
20. Rougier et al. J Clin Oncol 2005; 22 (14S): abstr. 3513.
21. Van Cutsem E et al. Ann Oncol 2005; 15 (Suppl. 3): abstr. 339P.
22. Seufferlein T, Dittrich C et al. A phase I/II study of cetuximab with 5-fluorouracil plus weekly oxliplatin in first – line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor. ASCO 2005; abstr. 3644.
23. Van Cutsem E, Nowacki M et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of pts with metastatic colorettal cancer. CRISTAL trial. ASCO 2007; abstr. 4000.
24. Bennouna J, Faroux R et al. UFT with LV, Irinotecan and cetuximab as first-line treatment for pts with metastatic colorectal cancer. ASCO 2007; Abstr. 4087.
25. Cartwright T, Kuefler P et al. Results of phase II trial of cetuximab + XELIRI as first-line therapy of pts with advanced colorectal cancer. ASCO 2007; Abstr. 4094.
26. Adam R et al. Ann Surg 240; 644–57: 2004.
27. Wein A et al. Ann Oncol 2001; 12: 1721–7.
28. Folprecht G et al. ASCO GI Symposium, 2004; abstr. 283. 
29. Van Cutsem E et al. Ann Oncol 2004; 15 (Suppl. 3): abstr. 339P.
30. Rougier P et al. J Clin Oncol 22 (14S): abstr. 3513.
31. Nagashima F, Zhang W et al. EGFR, Cox-2, EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer pts treated with single- agent cetuximab. ASCO 2007; Abstr. 4129.
32. Personeni N, De Hertogh G et al. Outcome prediction to cetuximab in advanced colorectal cancer. Analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridization. ASCO 2007; Abstr. 10569.
33. Finocchiaro G, Cappuzzo F et al. EGFR, HER 2, KRAS as predictive factors for cetuximab sensitivity in colorectal cancer. ASCO 2007; abstr. 4021.
34. Busam KJ, Capodieci P. Cutaneous side-effects in cancer pts treated with the anti-epidermal growth factor receptor antibody C225.Br J Dermatol 2004; 144: 1169–76.
35. Fiore F. Pessot F. KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. ASCO 2007; Abstr. 10502.
36. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
37. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
38. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman SA, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 2001; 797–860.
39. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to aplatinum-based chemotherapy. Clin Oncol (R. Coll. Radiol.) 2005; 17 (6): 418–24.
40. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824–8.
41. Vermorken JB et al. ASCO 2007; abstract and oral presentation №6091.
42. Baselga J et al. J Clin Oncol 2005; 23: 5568–77.
43. Vermorken JB et al. J Clin Oncol 2007; 25: 2171–7.